Jalava S
Scand J Rheumatol Suppl. 1983;48:5-9. doi: 10.3109/03009748309095333.
Twenty-eight patients with definite or classic rheumatoid arthritis were studied in a four-month double blind crossover trial. Patients were randomly divided into two groups, and received either carprofen, 300 mg/day, or indomethacin, 75 mg/day, for a period of two months, and then the other medication for a further two months. The classic procedures and measurements for evaluation of activity of rheumatoid arthritis were used. Laboratory tests were also carried out to assess toxicity. Both drugs were effective for the long term treatment of rheumatoid arthritis, and there were no statistically significant differences between the carprofen and indomethacin periods, or between groups. Although the incidence of adverse reactions was similar for both drugs, cutaneous symptoms were more frequent with carprofen than with indomethacin, whereas gastrointestinal and central nervous system reactions were found more often with indomethacin.
在一项为期四个月的双盲交叉试验中，对28例确诊或典型类风湿性关节炎患者进行了研究。患者被随机分为两组，一组接受每天300毫克的卡洛芬治疗，另一组接受每天75毫克的吲哚美辛治疗，为期两个月，然后再服用另一种药物两个月。采用了评估类风湿性关节炎活动度的经典程序和测量方法。还进行了实验室测试以评估毒性。两种药物对类风湿性关节炎的长期治疗均有效，卡洛芬组和吲哚美辛组治疗期间以及两组之间均无统计学上的显著差异。虽然两种药物的不良反应发生率相似，但卡洛芬引起的皮肤症状比吲哚美辛更常见，而吲哚美辛引起的胃肠道和中枢神经系统反应更常见。
